Department of Otorhinolaryngology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.
Department of Otorhinolaryngology, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.
Crit Rev Oncol Hematol. 2021 Apr;160:103298. doi: 10.1016/j.critrevonc.2021.103298. Epub 2021 Mar 11.
Recurrent early glottic cancer (rEGC) poses several issues in terms of timely diagnosis, correct re-staging, and treatment. We want to critically review the latest evidence about rEGC considering its epidemiology, biology, diagnostic challenges, and treatment strategies.
A systematic search of the literature using PubMed from 1990 to October 31, 2020 was performed.
There are many different treatment options available (open surgery, transoral mini-invasive surgery, radiotherapy), and many factors related to the patient's status and previous treatments must be considered when planning the best management strategy for rEGC. While its overall prognosis remains satisfactory, it is of the utmost importance to appreciate all the clinical implications derived from the choice of the initial therapeutic modality, and from a correct primary and recurrent staging.
The balance between oncological and voice and swallowing functions represents the fundamental principle underlying rEGC management. Future studies should focus on molecular profiling of rEGC, and on the results of the emerging radiation delivery techniques and mini-invasive procedures.
复发性早期声门癌（rEGC）在及时诊断、正确重新分期和治疗方面存在诸多问题。我们希望批判性地回顾 rEGC 的最新证据，考虑其流行病学、生物学、诊断挑战和治疗策略。
使用 PubMed 从 1990 年到 2020 年 10 月 31 日进行了系统的文献检索。
有许多不同的治疗选择（开放性手术、经口微创手术、放射治疗），在为 rEGC 制定最佳管理策略时，必须考虑与患者状况和先前治疗相关的许多因素。尽管其总体预后令人满意，但了解从初始治疗方式的选择和正确的原发性和复发性分期得出的所有临床意义非常重要。
肿瘤学和嗓音及吞咽功能之间的平衡是 rEGC 管理的基本原则。未来的研究应集中在 rEGC 的分子谱分析上，以及新兴的放射治疗技术和微创手术的结果上。
